Monalizumab

(Redirected from IPH2201)

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Monalizumab
Monoclonal antibody
Type?
SourceHumanized
TargetNKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII

Mechanism of action

edit

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]

References

edit
  1. ^ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  2. ^ IPH2201 studies
  3. ^ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  4. ^ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  5. ^ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
  6. ^ van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.